Cosmos Holdings

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Chicago, IL.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Earnings data Q1 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Thessaloniki, Greece.

Cosmos Health (NASDAQ: COSM ) stock is on the rise Friday after the pharmaceutical company secured a distribution agreement with Pharmalink. This agreement has Pharmalink acting as the exclusive distributor of Cosmos Health's Sky Premium Life products in the United Arab Emirates (UAE).

Why Is Cosmos Health (COSM) Stock Up 65% Today?

CHICAGO, IL / ACCESSWIRE / June 27, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has signed an exclusive distribution agreement (the "Agreement") with Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE). As part of the Agreement, Pharmalink will be responsible for all key functions, including sales and marketing, regulatory affairs, logistics, supply, and distribution of Sky Premium Life products in the UAE.

Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units

CHICAGO, IL / ACCESSWIRE / June 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an agreement to acquire all remaining rights arising from the patent filed with the World Intellectual Property Organization (WIPO) under reference code PCT/EP2023/071865. This follows the agreement announced on December 7, 2023, where Cosmos Health had acquired 60% of the rights.

Cosmos Health Strengthens Global Brain Tumor Market Position by Entering Agreement to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent

CHICAGO, IL / ACCESSWIRE / June 13, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the successful closing of the acquisition of the pharmacy distribution network owned by PELOFARM Ι.Κ.Ε. ("Pelofarm"), an established pharmaceutical wholesale company operating in the region of Arcadia, Greece, since 1985.

Cosmos Health Completes Acquisition of Pelofarm's Pharmacy Distribution Network; Annual Revenue Poised to Grow by Over $5 Million

CHICAGO, IL / ACCESSWIRE / May 17, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its successful participation in Vitafoods Europe 2024, the world's leading nutraceutical trade show. The event took place from May 14 to May 16, 2024, at Palexpo in Le Grand-Saconnex, Switzerland.

Cosmos Health Participated in Vitafoods Europe 2024; Receives Significant Interest and Numerous New Partnership Inquiries for its Sky Premium Life Nutraceuticals Brand

Innovage Holding Corp

Johnson & Johnson

The healthcare industry has experienced unprecedented growth in recent years due to the global pandemic. However, as COVID-19 began to ease, the immense growth of the healthcare industry is expected to slow down.

Stock Market Crash Warning: Don't Get Caught Holding These 3 Healthcare Stocks

CHICAGO, IL / ACCESSWIRE / April 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that, on April 17, 2024, it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") stating that, because the Company has not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the "Form 10-K"), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.

Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K

CHICAGO, IL / ACCESSWIRE / March 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the initiation of the development of Cloudscreen 2.0, the new iteration of its groundbreaking Artificial Intelligence (AI) drug repurposing platform. As previously announced, on January 23, 2024, Cosmos Health completed the acquisition of Cloudscreen.

Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform

CHICAGO, IL / ACCESSWIRE / March 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today it is in the final stages of securing regulatory approval to sell its biocide disinfectant hand soap, C-Scrub Wash 4% CHG ("C-Scrub"), in the United Kingdom (UK), and has obtained its inaugural purchase order. Cosmos Health expects to obtain all necessary registration approvals from the UK's Health Security Agency (HSA), an executive agency of the Department of Health and Social Care.

Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market

CHICAGO, IL / ACCESSWIRE / March 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received regulatory approval to sell its Sky Premium Life® vitamins and food supplements in the United Arab Emirates (UAE) market, and has obtained its inaugural purchase orders. Cosmos Health has obtained Consumer Product Registration Certificates ("Registration Certificates") from the Public Health & Safety Department of the Government of Dubai.

Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders

CHICAGO, IL / ACCESSWIRE / February 29, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the successful acquisition of the distribution network owned by Pharmatrade S.A. ("Pharmatrade"), an established pharmaceutical wholesale company operating in Greece.

Cosmos Health Successfully Completes Acquisition of Pharmatrade's Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million

CHICAGO, IL / ACCESSWIRE / February 20, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that on February 16, 2024, its CEO, Mr. Greg Siokas, acquired a total of 60,000 shares of the Company's common stock in the open market at an average price of $0.8301, for a total consideration of $49,806, demonstrating his strong belief in the Company and unwavering dedication to its continuous development.

Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company

CHICAGO, IL / ACCESSWIRE / February 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that Taglich Brothers, Inc. ("Taglich Brothers") has initiated coverage of the Company's common stock. The coverage and associated reports will be available at www.taglichbrothers.com.

Taglich Brothers Initiates Coverage of Cosmos Health Inc.

CHICAGO, IL / ACCESSWIRE / January 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has successfully completed the acquisition of Cloudscreen®, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023.

Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market

CHICAGO, IL / ACCESSWIRE / January 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has successfully completed the acquisition of the licenses and rights of a comprehensive portfolio of 10 generic drugs from a related party for €3.2 million, or approximately $3.5 million at today's exchange rate. This strategic acquisition significantly enhances Cosmos Health's pharmaceutical portfolio.

Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio

In 2023, Cosmos Health concluded multiple acquisitions, including Cana Laboratories, the distribution network owned by Bikas GP, and ZipDoctor. These acquisitions are projected to contribute almost $4 million in incremental group annual revenue in FY 2023.

Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023

CHICAGO, IL / ACCESSWIRE / December 20, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a definitive agreement, subject to customary closing conditions, with a related party to acquire the license and rights for "DIABIT-IS X", a drug used in the treatment of type-2 diabetes. DIABIT-IS X is one the first generics to be launched in Europe following the European patent expiration in June 2024 of the branded "Januvia" owned by Merck.

Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X

CHICAGO, IL / ACCESSWIRE / December 18, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Mr Greg Siokas, intends to purchase an aggregate of up to $3 million in common shares of the Company in the open market through December 31, 2024. So far in 2023, Mr.

Cosmos Health Announces Open Market Stock Purchases by the CEO

CHICAGO, IL / ACCESSWIRE / December 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, has announced the participation of its CEO, Greg Siokas, in Capital Link's Invest in Greece Forum (Accelerating Investments for Sustainable Growth). The event will take place on Monday, December 11, 2023, at The Metropolitan Club in New York City.

Cosmos Health to Participate at Capital Link's 'Invest in Greece' Forum in New York

CHICAGO, IL / ACCESSWIRE / December 7, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today an agreement with Cloudpharm PC to acquire the rights arising from the patent filed with the World Intellectual Property Organization (WIPO), under reference code PCT/EP2023/071865. The patent filing describes the repurposing of an existing drug to act on the Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), a key target in various diseases.

Cosmos Health Enters into Agreement to Acquire Rights for WIPO-Filed Patent on Drug Targeting CNS Cancers

CHICAGO, IL / ACCESSWIRE / December 1, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has filed a patent application with the European Patent Office (EPO) under reference code PCT/EP2023/083947 (filing date December 1, 2023) for its CCX0722 obesity and weight management product. This marks an important milestone in the Company's dynamic and growing R&D pipeline, emphasizing its commitment to safeguarding intellectual property and fueling the growth of its innovative healthcare solutions.

Cosmos Health Announces Patent Filing for its Obesity and Weight Management Product

THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023. Third Quarter 2023 Financial Highlights Revenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded following the acquisition of the Bikas GP pharmacy distribution network.

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

CHICAGO, IL / ACCESSWIRE / October 11, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a purchase agreement to acquire Cloudscreen®, a revolutionary Artificial Intelligence (AI) powered platform. Cloudscreen® is a multimodal platform for drug repositioning and repurposing.

Cosmos Health to Acquire Cloudscreen, a Cutting-Edge AI-Powered Drug Repurposing Platform; Anticipated to Establish Cosmos as a Leader in the $25Bn Global Market and Deliver Unparalleled Returns for Shareholders

Company reaches major strategic inflection point, with operations and revenue ramp-up underway, to significantly accelerate in 2024 and beyond Maintains solid balance sheet with negligible debt and strong, diversified asset base Book value exceeds $4 per share, which is more than 3x current share price Tangible assets, including unencumbered freehold properties, have a fair market value exceeding $12M, which is more than 50% of current market capitalization In H1 2023, Adjusted EBITDA and Adjusted Net Income each surpassed $3 million Inaugural 2026 guidance introduced; expects to achieve over $180M in gross annual revenue and EBITDA in excess of $20M Successfully completed 3 acquisitions so far in 2023, with more in the pipeline Notable progress in R&D, with products advancing through various stages, including clinical trials Nutraceutical brands, Sky Premium Life and Mediterranation, experiencing significant market success, expanding into new markets globally Announced re-launch of bio-bebe and expansion of C-Sept with the launch of C-Scrub Wash Actively exploring initiatives to enhance value, including, among others, spinning off R&D division into a standalone, publicly listed biotech company Returning capital to shareholders: execution of share buyback program underway CEO Greg Siokas has invested more than $15M since inception, including almost $1M YTD CHICAGO, IL / ACCESSWIRE / October 5, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today announces that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders. Dear Fellow Cosmos Health Shareholders, I am pleased to communicate directly with you to share the many exciting developments in our Company.

COSMOS HEALTH CEO Issues Letter to Shareholders

Centene

iBio

The healthcare industry has historically provided significant returns to investors. And, it is currently boasting a compounding annual growth rate prediction of 10.4% until 2027.

News for Cosmos Holdings Stock (COSM)